I 

108TH CONGRESS 

2D SESSION H. R. 3866

To amend the Controlled Substances Act to provide increased penalties for 

anabolic steroid offenses near sports facilities, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 1, 2004

Mr. SENSENBRENNER (for himself, Mr. CONYERS, Mr. SWEENEY, Mr. 

OSBORNE, and Mr. BERMAN) introduced the following bill; which was referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions 

as fall within the jurisdiction of the committee concerned 

A BILL

To amend the Controlled Substances Act to provide increased 

penalties for anabolic steroid offenses near sports facilities, and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Anabolic Steroid Con5 trol Act of 2004’’. 
2

•HR 3866 IH 

1 SEC. 2. INCREASED PENALTIES FOR ANABOLIC STEROID 

2 OFFENSES NEAR SPORTS FACILITIES. 

3 (a) IN GENERAL.—Part D of the Controlled Sub4 stances Act is amended by adding at the end the following: 

5 ANABOLIC STEROID OFFENSES NEAR SPORTS FACILITIES

6 ‘‘SEC. 424. (a) Whoever violates section 401(a)(1) or 

7 section 416 by manufacturing, distributing, or possessing 

8 with intent to distribute, an anabolic steroid near or at 

9 a sports facility is subject to twice the maximum term of 

10 imprisonment, maximum fine, and maximum term of su11 pervised release otherwise provided by section 401 for that 

12 offense. 

13 ‘‘(b) As used in this section—

14 ‘‘(1) the term ‘sports facility’ means real prop15 erty where athletic sports or athletic training takes 

16 place, if such property is privately owned for com17 mercial purposes or if such property is publicly 

18 owned, but does not include any real property de19 scribed in section 419; 

20 ‘‘(2) the term ‘near or at’ means in or on, or 

21 within 1000 feet of; and 

22 ‘‘(3) the term ‘possessing with intent to dis23 tribute’ means possessing with the intent to dis24 tribute near or at a sports facility.’’. 

25 (b) TABLE OF CONTENTS AMENDMENT.—The table 

26 of contents for Comprehensive Drug Abuse Prevention 
3

•HR 3866 IH 

1 and Control Act of 1970 is amended by inserting after 

2 the item relating to section 423 the following new item:

‘‘424. Increased Penalties for Anabolic Steroid Offenses Near Sports Facilities.’’.

3 SEC. 3. SENTENCING COMMISSION GUIDELINES. 

4 The United States Sentencing Commission shall—

5 (1) review the Federal sentencing guidelines 

6 with respect to offenses involving anabolic steroids; 

7 (2) consider amending the Federal sentencing 

8 guidelines to provide for increased penalties with re9 spect to offenses involving anabolic steroids in a 

10 manner that reflects the seriousness of such offenses 

11 and the need to deter anabolic steroid use; and 

12 (3) take such other action that the Commission 

13 considers necessary to carry out this section. 

14 SEC. 4. AMENDMENTS TO THE CONTROLLED SUBSTANCES 

15 ACT. 

16 (a) DEFINITIONS.—Section 102 of the Controlled 

17 Substances Act (21 U.S.C. 802) is amended—

18 (1) in paragraph (41)—

19 (A) by realigning the margin so as to align 

20 with paragraph (40); and 

21 (B) by striking subparagraph (A) and in22 serting the following: 

23 ‘‘(A) The term ‘anabolic steroid’ means any drug or 

24 hormonal substance, chemically and pharmacologically re-
4

•HR 3866 IH 

1 lated to testosterone (other than estrogens, progestins, 

2 corticosteroids, and dehydroepiandrosterone), and in3 cludes—

4 ‘‘(i) androstanediol—

5 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 

6 ‘‘(II) 3α,17β-dihydroxy-5α-androstane; 

7 ‘‘(ii) androstanedione (5α-androstan-3,17-

8 dione); 

9 ‘‘(iii) androstenediol—

10 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy11 5α-androst-1-ene); 

12 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy13 5α-androst-1-ene); 

14 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy15 androst-4-ene); and 

16 ‘‘(IV) 5-androstenediol (3b,17β-dihydroxy17 androst-5-ene); 

18 ‘‘(iv) androstenedione—

19 ‘‘(I) 1-androstenedione ([5α]-androst-1-en20 3,17-dione); 

21 ‘‘(II) 4-androstenedione (androst-4-en22 3,17-dione); and 

23 ‘‘(III) 5-androstenedione (androst-5-en24 3,17-dione);
5

•HR 3866 IH 

1 ‘‘(v) bolasterone (7α,17α-dimethyl-17β2 hydroxyandrost-4-en-3-one); 

3 ‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene4 3-one); 

5 ‘‘(vii) calusterone (7β,17α-dimethyl-17β6 hydroxyandrost-4-en-3-one); 

7 ‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4-

8 en-3-one); 

9 ‘‘(ix) dehydrochlormethyltestosterone (4-chloro10 17β-hydroxy-17α-methyl-androst-1,4-dien-3-one); 

11 ‘‘(x) 4-dihydrotestosterone (17β-hydroxy12 androstan-3-one); 

13 ‘‘(xi) drostanolone (17β-hydroxy-2α-methyl-5α14 androstan-3-one); 

15 ‘‘(xii) ethylestrenol (17α-ethyl-17β-hydroxyestr16 4-ene); 

17 ‘‘(xiii) fluoxymesterone (9-fluoro-17α-methyl18 11β,17β-dihydroxyandrost-4-en-3-one); 

19 ‘‘(xiv) formebolone (2-formyl-17α-methyl20 11α,17β-dihydroxyandrost-1,4-dien-3-one); 

21 ‘‘(xv) furazabol (17α-methyl-17β22 hydroxyandrostano[2,3-c]-furazan); 

23 ‘‘(xvi) 18α-homo-17β-hydroxyestr-4-en-3-one 

24 (13β-ethyl-17β-hydroxygon-4-en-3-one); 
6

•HR 3866 IH 

1 ‘‘(xvii) 4-hydroxytestosterone (4,17β-dihydroxy2 androst-4-en-3-one); 

3 ‘‘(xviii) 4-hydroxy-19-nortestosterone (4,17β4 dihydroxy-estr-4-en-3-one); 

5 ‘‘(xix) mestanolone (17α-methyl-17β-hydroxy6 5α-androstan-3-one); 

7 ‘‘(xx) mesterolone (1α-methyl-17β-hydroxy8 [5α]-androstan-3-one); 

9 ‘‘(xxi) methandienone (17α-methyl-17β10 hydroxyandrost-1,4-dien-3-one); 

11 ‘‘(xxii) methandriol (17α-methyl-3β,17β12 dihydroxyandrost-5-ene); 

13 ‘‘(xxiii) methenolone (1-methyl-17β-hydroxy-5α14 androst-1-en-3-one); 

15 ‘‘(xxiv) methyltestosterone (17α-methyl-17β16 hydroxyandrost-4-en-3-one); 

17 ‘‘(xxv) mibolerone (7α,17α-dimethyl-17β18 hydroxyestr-4-en-3-one); 

19 ‘‘(xxvi) nandrolone (17β-hydroxyestr-4-en-3-

20 one); 

21 ‘‘(xxvii) norandrostenediol—

22 ‘‘(I) 19-nor-4-androstenediol (3β, 17β23 dihydroxyestr-4-ene); 

24 ‘‘(II) 19-nor-4-androstenediol (3α, 17β25 dihydroxyestr-4-ene); 
7

•HR 3866 IH 

1 ‘‘(III) 19-nor-5-androstenediol (3β, 17β2 dihydroxyestr-5-ene); and 

3 ‘‘(IV) 19-nor-5-androstenediol (3α, 17β4 dihydroxyestr-5-ene); 

5 ‘‘(xxviii) norandrostenedione—

6 ‘‘(I) 19-nor-4-androstenedione (estr-4-en7 3,17-dione); and 

8 ‘‘(II) 19-nor-5-androstenedione (estr-5-en9 3,17-dione; 

10 ‘‘(xxix) norbolethone (18α-homo-17β11 hydroxypregna-4-en-3-one); 

12 ‘‘(xxx) norclostebol (4-chloro-17β-hydroxyestr-4-

13 en-3-one); 

14 ‘‘(xxxi) norethandrolone (17α-ethyl-17β15 hydroxyestr-4-en-3-one); 

16 ‘‘(xxxii) oxandrolone (17α-methyl-17β-hydroxy17 2-oxa-[5α]-androstan-3-one);

18 ‘‘(xxxiii) oxymesterone (17α-methyl-4,17β19 dihydroxyandrost-4-en-3-one); 

20 ‘‘(xxxiv) oxymetholone (17α-methyl-2-

21 hydroxymethylene-17β-hydroxy-[5α]-androstan-3-

22 one); 

23 ‘‘(xxxv) stanozolol (17α-methyl-17β-hydroxy24 [5α]-androst-2-eno[3,2-c]-pyrazole); 
8

•HR 3866 IH 

1 ‘‘(xxxvi) stenbolone (17β-hydroxy-2-methyl2 [5α]-androst-1-en-3-one); 

3 ‘‘(xxxvii) testolactone (13-hydroxy-3-oxo-13,17-

4 secoandrosta-1,4-dien-17-oic acid lactone); 

5 ‘‘(xxxviii) 1-testosterone (17β-hydroxy-5α6 androst-1-en-3-one); 

7 ‘‘(xxxix) testosterone (17β-hydroxyandrost-4-en8 3-one); 

9 ‘‘(xl) tetrahydrogestrinone (13β,17α-diethyl10 17β-hydroxygon-4,9,11-trien-3-one); 

11 ‘‘(xli) trenbolone (17β-hydroxyestr-4,9,11-trien12 3-one); and 

13 ‘‘(xlii) any salt, ester, or ether of a drug or sub14 stance described in this paragraph.’’; and 

15 (2) in paragraph (44), by inserting ‘‘anabolic 

16 steroids,’’ after ‘‘marihuana,’’. 

17 (b) AUTHORITY AND CRITERIA FOR CLASSIFICA18 TION.—Section 201(g) of the Controlled Substances Act 

19 (21 U.S.C. 811(g)) is amended—

20 (1) in paragraph (1), by striking ‘‘substance 

21 from a schedule if such substance’’ and inserting 

22 ‘‘drug which contains a controlled substance from 

23 the application of titles II and III of the Comprehen24 sive Drug Abuse Prevention and Control Act (21 

25 U.S.C. 802 et seq.) if such drug’’; and 
9

•HR 3866 IH 

1 (2) in paragraph (3), by adding at the end the 

2 following: 

3 ‘‘(C) Upon the recommendation of the Sec4 retary of Health and Human Services, a compound, 

5 mixture, or preparation which contains any anabolic 

6 steroid, which is intended for administration to a 

7 human being or an animal, and which, because of its 

8 concentration, preparation, formulation or delivery 

9 system, does not present any significant potential for 

10 abuse.’’.

Æ